Oragenics has activated a second clinical site at Alfred Hospital for its Phase IIa trial of ONP-002, a drug candidate for treating concussion and mild traumatic brain injury (mTBI). The trial, already enrolling patients at Mackay Base Hospital in Australia, aims to enroll 40 patients to evaluate ONP-002's effectiveness in reducing brain inflammation and injury symptoms. This drug could become the first FDA-approved pharmacological treatment for concussion, addressing a significant unmet medical need. Data from this trial is expected by the end of 2026, supporting a planned Phase IIb trial in the U.S.
YD Bio Limited's U.S. affiliate, EG BioMed US, has secured clinical lab licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified, CAP-accredited lab's footprint to 46 states plus D.C. and Guam. This expansion enhances patient access to...
Diffusion, a global communications agency, is growing its home and interiors portfolio by signing new clients including POVISON (furniture), LUSA Lighting, and Induction Hardware (appliances). The agency will support these premium brands with integra...
Heathrow Finance PLC announced a €350 million offering of 4-year senior secured notes with a stabilization period starting July 2, 2026, and ending by August 7, 2026. BNP Paribas and other major banks will manage the stabilization to support the bond...
Polibeli Group Ltd. has signed a non-binding Memorandum of Understanding with AUTHAIKAM COMPANY LIMITED to jointly evaluate a potential 100 MW AI computing center project in Thailand. The collaboration involves preliminary assessments such as site vi...
Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed its share dealings on July 1, 2026. The bank purchased 575,000 ordinary shares at prices between 280.1318 and 280.5, and sold 582,547 shares at p...
